AOD-9604
$40.99 – $68.99Price range: $40.99 through $68.99
A modified fragment of human growth hormone (residues 176-191) developed specifically for fat loss without GH’s other hormonal effects.
Molecular & analytical data
Verified chemistry and third-party reference identifiers for this compound.

Reconstitution calculator
Concentration, volume per draw, and the graduation it measures to. Open the full bench calculator with this vial loaded →
—
A U-100 insulin syringe reads 100 units per 1 mL. Figures describe the contents of a vial for laboratory handling reference only and are not dosing guidance.
Quality & verification
Every batch is characterised before release and ships with documentation.
Storage & handling
Keep the peptide stable from delivery through reconstitution.
Lyophilized at -20°C. Reconstituted at 2-8°C.
AOD-9604 is a peptide fragment of human growth hormone (HGH) consisting of amino acids 176-191, with the addition of a tyrosine at the C-terminus. It was developed specifically to isolate the fat-burning properties of HGH without its growth-promoting or diabetogenic effects. AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) without affecting blood sugar levels or promoting growth. Early research also suggested potential benefits for cartilage repair and joint health, leading to TGA (Australian) approval as an injectable for osteoarthritis in that market.
Certificates of Analysis
Every batch of this peptide is tested before release. Find the batch number printed on your vial and verify or download its certificate.
| Batch # | Issued | Purity | Certificate |
|---|---|---|---|
| NHV26-R5120 COA-SVD2-YMQV-9 | 04 Aug 2026 | 98.47 % HPLC | Verify at IRZC ↗ |
“Verify at IRZC” opens the laboratory’s own record for that certificate, on their site. Looking for an older batch we haven’t published? Email [email protected] with the batch number from your vial — we keep all certificates for 7 years.
The information below summarises published preclinical and clinical research for scientific reference. NHOV products are sold strictly for laboratory research use only. Nothing here is medical advice, a recommendation, or an instruction for use in humans or animals.
Mechanism of action
Stimulates lipolysis by a mechanism not directly mediated through the beta-3 adrenergic receptor, although treatment increases beta-3 adrenergic receptor expression, inhibits lipogenesis, does not affect IGF-1 or insulin sensitivity, potential cartilage chondrocyte stimulation. Acts on fat cells without full GH receptor activation.
Primary uses / indications
Fat loss, weight management, body composition, cartilage repair research, joint health
Typical dosage (reported)
250-500 mcg daily, injected into abdominal fat (targeted). Often taken fasting in the morning.
Cycle duration (reported)
12-24 weeks for body composition research
Administration route
Subcutaneous injection, Oral (emerging research)
Side effects (reported)
Injection site reactions, headache, mild nausea. Generally well-tolerated in clinical studies. FDA cites immunogenicity concerns.
Contraindications
Active cancer, pregnancy/breastfeeding, known hypersensitivity
Drug interactions
No significant GH-axis interactions. Does not affect insulin or blood glucose.
Identity
| Full name / brand names | AOD-9604 (Advanced Obesity Drug-9604) |
|---|---|
| Category | Growth Hormone Secretagogues |
| Subcategory | HGH Fragment / Fat Loss |
| Origin / source | Synthetic; fragment of human growth hormone |
| Year discovered | 1990s-2000s (Monash University, Australia) |
Chemistry
| Amino acid sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (Tyr-hGH(177-191); 16 amino acids, N-terminal Tyr in place of hGH Phe176; cyclic Cys7-Cys14 disulfide) |
|---|---|
| Molecular formula | C78H123N23O23S2 |
| Molecular weight | 1815.08 g/mol |
| CAS number | 221231-10-3 |
| PubChem CID | CID 71300630 ↗ |
| Purity standard | ≥98% |
Pharmacokinetics
| Half-life | Not established |
|---|---|
| Bioavailability | Subcutaneous: moderate; Oral: low |
Regulatory & research status
| FDA status | Not FDA-approved. Proposed by FDA to not be included on bulk drug substances list. Prohibited for compounding due to safety concerns. |
|---|---|
| Prescription required | Research use only in US; available by prescription in some countries |
| Research status | Phase IIb clinical trials for obesity; development halted after poor efficacy. Not FDA-approved. |
| Clinical trials | Phase IIa/IIb (OPTIONS trial, obesity; terminated 2007 for lack of efficacy) |
References
Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM, "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out mice", Endocrinology, 2001;142(12):5182-5189, DOI: 10.1210/endo.142.12.8522; Stier H, Vos E, Kenley D, "Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans", Journal of Endocrinology and Metabolism, 2013;3(1-2):7-15
Frequently asked questions
What is AOD-9604?
How does AOD-9604 work?
What AOD-9604 dosage is used in research?
What is the half-life of AOD-9604?
How should AOD-9604 be stored and reconstituted?
What purity is NHOV's AOD-9604?
Is AOD-9604 approved for human use?
Related products
HGH Fragment 176-191
C-terminal 16-mer of human growth hormone studied in lipolysis research.
$39.99 – $60.99Price range: $39.99 through $60.99
Pre-order 5-Amino-1MQ
Small-molecule NNMT inhibitor studied in NAD+ and energy metabolism research.
$36.99 – $50.99Price range: $36.99 through $50.99SLU-PP-332
ERR nuclear receptor agonist investigated as an exercise-mimetic compound.
$54.99 – $80.99Price range: $54.99 through $80.99
Pre-order 
AICAR
Nucleoside analog and AMPK activator studied in cellular metabolism research.
$34.99 – $54.99Price range: $34.99 through $54.99
Pre-order
Pre-order








Reviews
Clear filtersThere are no reviews yet.